Visioneering Technologies Inc's NaturalVue Multifocal 1 Day Contact Lenses showed promising results in the second phase of findings from the 3-year PROTECT study.
Year-2 preliminary data findings reveal a significant reduction in refractive error (53%) and axial length growth (86%) compared to the control group, and is said to support the NaturalVue Multifocal’s effectiveness in controlling myopia progression across diverse patient populations.
VTI’s chief medical officer Dr. Ashley Tuan said Year 1 findings of 'clear vision, safety, and comfort, leading to high compliance and effective outcomes', was expected to continue into Year 2 findings.
VTI CEO and executive director Dr. Juan Carlos Aragón concluded: 'Based on the results from all recent clinical studies, NaturalVue Multifocal may be the only myopia management lens that can reduce vision challenges in all types of children.'
Meanwhile, a clinical trial led by the Universidad Complutense de Madrid validated the Multifocal 1 Day CL's ability to correct 100% of astigmatism up to 2.00D on myopic children, with an 83% success rate when up to 3.00D.
